Future research should focus on elucidating the regulatory networks of SphK1/SphK2 in different HCC subtypes, developing highly selective inhibitors, and advancing clinical trials based on metabolic-immune interaction regulation. Here, SPHK1 is linked to hepatocellular carcinoma.